Involvement of CD4+CD25+ regulatory T cells in the pathogenesis of polycythaemia vera

Chinese Medical Journal

Volumn 121, Issue 18, 2008, Pages 1781-1786

  Zhao, Wen Bo ^a   Li, Ying ^a   Liu, Xin ^a   Zhang, Ling Yan ^a   Wang, Xin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Pathogenesis; Polycythaemia vera; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RISK FACTOR;

EID: 54349116243     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200809020-00005     Document Type: Article

References (30)

1. Maran J, Prchal J. Polycythemia and oxygen sensing. Pathol Biol 2004; 52: 280-284.
2. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ III. Trends in the incidence of polycythemia vera among olmsted county, Minnesota residents, 1935-1989. Am J Hematol 1994; 47: 89-93.
3. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-447.
4. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370-3377.
5. Jamieson CHM, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 2006; 103: 6224-6229.
6. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
7. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
8. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
9. + cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytes. Br J Haematol 2005; 130: 797-799.
10. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
11. Hong X, Wu QY, Hu HG, Liu B, Guo W, Sze DMY, et al. Enhanced interferon-gamma secretion and antitumor activity of T-lymphocytes activated by dendritic cells loaded with glycoengineered myeloma antigens. Chin Med J 2007; 120: 1678-1684.
12. + and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004; 112: 258-267.
13. + regulatory T cells suppress NK T cell functions. Cancer Res 2003; 63: 4516-4520.
14. + T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front Biosci 2006; 11: 1360-1370.
15. + regulatory T cells. Int Immunol 2004; 16: 1643-1656.
16. Paul CC, Baumann MA. Impaired interleukin-2 production by T-lymphocytes in polycythemia vera. J Clin Lab Anal 1989; 3: 84-87.
17. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
18. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Res 2005; 65: 2457-2464.
19. + regulatory T cells. Nat Immunol 2003; 4: 330-336.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
21. + T cells. Blood 2005; 105: 1484-1491.
22. Rueda F, Remacha A, Martí F, Piñol G, Soler J, Guañabens C, et al. Different lymphocyte activity in patients with polycythaemia vera versus secondary polycythaemia and healthy blood donors. Acta Haematol 1990; 83: 31-34.
23. + suppressor T cells. Immunol Rev 2001; 182: 58-67.
24. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296.
25. + regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110: 847-850.
26. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145-10152.
27. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
28. Kotsianidis I, Silk JD, Spanoudakis E, Patterson S, Almeida A, Schmidt RR, et al. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood 2006; 107: 3138-3144.
29. + T cells by suppressive subtractive hybridization. Chin Med J 2007; 120: 1326-1330.
30. + regulatory T cells. Proc Natl Acad Sci U S A 2006; 103: 5460-5465.